Herzum Astrid, Trave Ilaria, D'Agostino Federica, Burlando Martina, Cozzani Emanuele, Parodi Aurora
Department of Dermatology, Di.S.Sal., University of Genoa, San Martino Polyclinic Hospital IRCCS, Genoa, Italy.
Clin Exp Vaccine Res. 2022 May;11(2):222-225. doi: 10.7774/cevr.2022.11.2.222. Epub 2022 May 31.
We present the case of a 24-year-old Caucasian man, who developed a scaly erythematous skin rash after the second dose of coronavirus disease 2019 (COVID-19) vaccination with Comirnaty (BNT162b2, BioNTech/Pfizer; Pfizer, New York, NY, USA) and proved positive for Epstein-Barr virus (EBV) reactivation. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines have been associated with an up-regulated T helper type 1-cell response, possibly favoring an immune system imbalance. Also, EBV reactivation has been postulated after COVID-19 vaccination, but only in the immunosuppressed. Noteworthy we report the first case of EBV viral reactivation associated with cutaneous manifestations in an immunocompetent patient after the COVID-19 vaccine.
我们报告了一名24岁的白种男性病例，该患者在接种第二剂Comirnaty（BNT162b2，BioNTech/辉瑞公司；美国纽约州辉瑞公司）的2019冠状病毒病（COVID-19）疫苗后出现了鳞屑性红斑皮疹，并被证明存在爱泼斯坦-巴尔病毒（EBV）再激活。严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗与上调的1型辅助性T细胞反应有关，这可能会导致免疫系统失衡。此外，有人推测COVID-19疫苗接种后会出现EBV再激活，但仅发生在免疫抑制患者中。值得注意的是，我们报告了首例在免疫功能正常的患者中，COVID-19疫苗接种后出现与皮肤表现相关的EBV病毒再激活病例。
